Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Earnings Data
Report Date
Nov 06, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
<0.01Last Year’s EPS
-0.11Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and growth, particularly in revenue and product demand. Key products like Recorlev showed exceptional growth, and the company successfully raised its revenue guidance. However, there were challenges with increased expenses affecting gross margin and SG&A costs.Company Guidance
Record-Breaking Revenue and Growth
Total revenue grew 49% year-over-year to a quarterly record of $71.5 million. The company raised its full-year revenue guidance to $280 million to $290 million, representing a 40% year-over-year growth at the midpoint.
Exceptional Growth of Recorlev
Recorlev revenue grew 136% year-over-year to $31.4 million, with the average number of patients on therapy increasing by 122%. This performance reinforces Recorlev's position as a key treatment option for Cushing's syndrome.
Positive Adjusted EBITDA
The company reported a positive adjusted EBITDA of $12.5 million, reflecting an improvement of nearly $13 million compared to the previous year.
Successful Analyst and Investor Day
The company's first-ever Analyst and Investor Day outlined the long-term vision and key growth drivers, notably Recorlev and the pipeline asset XP-8121, receiving positive engagement from the investment community.
Gvoke and Keveyis Steady Growth
Gvoke posted a 17% increase in revenue to $23 million, while Keveyis demonstrated its importance with revenue over $11 million, marking a modest increase.
XERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $5.49 | $6.60 | +20.22% |
May 08, 2025 | $4.48 | $5.16 | +15.18% |
Mar 06, 2025 | $3.77 | $4.13 | +9.55% |
Nov 08, 2024 | $3.36 | $3.47 | +3.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xeris Pharmaceuticals (XERS) report earnings?
Xeris Pharmaceuticals (XERS) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).
What is Xeris Pharmaceuticals (XERS) earnings time?
Xeris Pharmaceuticals (XERS) earnings time is at Nov 06, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XERS EPS forecast?
XERS EPS forecast for the fiscal quarter 2025 (Q3) is <0.01.